Biotinidase Deficiency in Newborns as Respiratory Distress and Tachypnea: A Case Report

How to Cite This Article: Kohmanaee Sh, Zarkesh M, Tabrizi M, Hassanzadeh Rad A, Divshali S, Dalili S. Biotinidase Deficiency in Newborns as Respiratory Distress and Tachypnea: A Case Report. Iran J Child Neurol. Spring 2015; 9(2):58-60.

Abstract

Objective
Biotin is a coenzyme composed of four carboxylases. It presents in amino acid catabolism, fatty acid synthesis, and gluconeogenesis. Biotinidase recycles the vitamin biotin. A biotinidase deficiency is a neurocutaneous disorder with autosomal recessive inheritance. The symptoms can be successfully treated or prevented by administering pharmacological doses of biotin. Although, according to neonatal prenatal medicine (2011), a biotinidase deficiency does not manifest during the neonatal period. In this study, we report on a case of biotinidase deficiency in the first week of birth.

Case Report
A 3100 g term boy was born via cesarean section. After 3 days, he was referred to the 17th Shahrivar Hospital with the chief complaint of tachypnea and grunting. Laboratory results revealed that liver and renal function tests, serum electrolytes, and blood indexes except ammonia were all normal. Within few days after the administration of oral biotin, the patient showed dramatic improvement and was discharged. However, within 4 months he was admitted two other times with the complaints of diarrhea and pneumonia. Unfortunately, he expired after 4 months.

According to our results, it seems that clinicians should accurately assess suspicious patients and even assess infants for biotinidase deficiency.

Keywords: Biotinidase Deficiency; Biotin, Newborn; Children

Introduction
Biotin is a coenzyme composed of four carboxylases. It is commonly present in amino acid catabolism, fatty acid synthesis, and gluconeogenesis (1, 2). Biotinidase deficiency (BD) is an autosomal recessive disorder that originates by a deficiency of the biotinidase enzyme. The incidence of combined (partial and profound) and profound BD were reported as 1 per 60,089 and 1 per 112,271 of live births, respectively (3). Biotinidase recycles the vitamin biotin. Although, BD has a fundamental influence on neurocutaneous organs and as a cause of neurological disorders, it is, however, indicated by symptoms that can be effectively treated or prevented with therapeutic doses of biotin. In addition, untreated BD can be mentioned as an ideal example of an inherited metabolic disorder that can induce major disabilities (3). Although, most BD patients demonstrate metabolic ketolactic acidosis, organic aciduria, and mild hyperammonemia, it is asymptomatic in
children without the presence of organic aciduria or metabolic ketoacidosis and the diagnosis of BD should be performed (4-6). Recently, BD is indicated as a major criterion for newborn screening and is universally approved in the United States as well as other countries (3). BD can be detected by newborn screening or prenatal molecular analysis for mutations. Clinicians usually recommend prenatal molecular analysis in patients with previous familial affected child because of the discovery of carrier states (6).

According to neonatal prenatal medicine, BD does not present in the neonatal period (2, 7). However, in this study, we report a case of BD in the first week after birth.

**Fig 1:** A 3 days old boy who referred to hospital with the chief complaint of tachypnea and grunting

**Case Report**

A 3100 gram term boy was born through cesarean section. He was the second born child of consanguineous marriage and did not receive vaccinations at birth. Three days after birth, he was referred to 17th Shahrivar Hospital with a chief complaint of tachypnea and grunting. The anterior fontanel was not bulged and he was conscious but ill during the physical examination. He had grunting and intercostal retraction. A 2/6 systolic murmur at LSB was heard and based on the pediatric cardiologist examination; a heart abnormality was not mentioned.

O2 sat = 99%, RR = 58, PR = 156

Laboratory studies revealed that liver and renal function tests, serum electrolytes, and blood indexes except ammonia were all normal (Table 1).

In addition, a sepsis workup including blood, urine, and CSF culture had been done and results indicated negative growth. Further, results indicated persistent severe metabolic acidosis based on ABG (pH: 7.01, Po2: 169.4, Pco2: 20.4, Hco 3: 7, and O 2 sat 99 %).

In addition, CL and Na had been assessed and a high anion gap metabolic acidosis had been noted and was treated by 40 meq Hco3 (7.5%) or 13 meq/kg/day. According to parental interfamilial marriage and high anion gap metabolic acidosis, the clinicians decided to detect for metabolic disorders such as ammonia, lactate, tendon mass spectrum, and urine organic acid. Further, increased lactate and ammonia was observed. Our results showed abnormalities in the blood and urine. The presence of 3-hydroxyisovalerylcarnitine (C5-OH) and decreased biotinidase enzyme indicated BD. Within few days after administration of oral biotin (10 mg / day), the patient showed dramatic improvement by normalization of blood gas analysis. Therefore, clinicians recommended discharge after 20 days. However, within 4 months, he was admitted two other times with the complaints of diarrhea and pneumonia. Unfortunately, he expired after 4 months.

**Discussion**

An infant with early presentation of BD was described. On admission, he had severe neurologic symptoms and by administering continuous biotin showed dramatic improvement. In addition, previous investigations recommended continued biotin therapy (8, 9). Unfortunately, on time and accurate diagnosis and treatments could not prevent further complications and the child expired after 4 months. It seems that it happened because of immunodeficiency combined with BD led to his expiration (10).

In this study, we reported BD in the neonatal period. However, Zinn et al mentioned that BD does not manifest in the neonatal period (2), which is inconsistent with our results. Also, Andersen et al noted 2- and 3-weeks as the earliest reported age for BD (7).

No complaint of seizure was mentioned in the current study. However, Venkataraman et al mentioned seizure as the presenting complaint in all patients and clonic seizure was the predominant seizure type (11). Moreover, Bunch et al mentioned that seizure was a common feature (55 % in Salbert series) and usually an initial symptom (38 %) in profound BD. They also noted generalized tonic–clonic (56 %) seizures (12).

Moreover, in this study the patient had persistent severe metabolic acidosis, which was inconsistent with Venkataraman et al. In addition, Venkataraman et al noted acidosis in no patients (11).
Furthermore, in this study, results showed abnormality in both blood and urine 3-hydroxyisovalerylcarmitine (C5-OH) and indicated BD. However, a previous investigation indicated increased blood 3-hydroxyisovalerylcarmitine (C5-OH) in beta-ketothiolase deficiency, 3methylcrotonyglycinuria, biotinidase deficiency, 3-hydroxyisobutyric aciduria (13) As decreased levels of biotinidase enzyme by ELIZA in filter paper had been reported and may indicate a BD diagnosis, which should be confirmed by genetic methods.

In conclusion, according to our results, it seems that clinicians should accurately assess suspicious patients and even assess infants for BD.

Table 1. Results of the laboratory tests

| Laboratory tests | result | Normal range           |
|------------------|--------|------------------------|
| K                | 5.2    | 3.4–5.3 mmol /L         |
| Na               | 137    | 137–147 mmol /L         |
| Cl               | 102    | 99–108 mmol /L         |
| Ca               | 9.5    | 8.7–10.7 mg /dL        |
| Lactate          | 4      | 0.9–1.8 mmol /L        |
| Ammonia          | 150    | 25–80 mmol /L          |
| FBS              | 85     | 60–99 mg /dL          |
| BUN              | 7      | 5–18 mg /dL           |
| Cr               | 0.7    | 0.75–1.20 mg /dL       |

Acknowledgements
We appreciate the colleagues who cooperated in this study.

Author Contribution
Dr Koohmankaee: conceptualized and designed the study, and drafted the initial manuscript and reviewed and revised the manuscript.
Dr Zarkesh: conceptualized and designed the study, and drafted the initial manuscript and reviewed and revised the manuscript.
Dr. Tabrizi: coordinated and supervised data collection, critically reviewed the manuscript.
Afagh Hassanzadeh Rad: drafted the initial manuscript and reviewed and revised the manuscript.
Siamak Diveshali:
Dr Dali: conceptualized and designed the study, and drafted the initial manuscript and reviewed and revised the manuscript.
All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

References
1. Monnot S, Serre V, Chadefaux-Vekemans B, Aupetit J, Romano S, De Lonlay P, et al. Structural insights on pathogenic effects of novel mutations causing pyruvate carboxylase deficiency. Human Mutation. 2009; 30(5):734-40.
2. Zinn A. Inborn error of metabolism. In: Martin RJ Fa, Walsh MC, editor. Fanaroff and Martin's Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant-Expert Consult2010. p. 1624-38.
3. Wolf B. Worldwide survey of neonatal screening for biotinidase deficiency. Journal of inherited metabolic disease. 1991;14(6):923-7.
4. Thodi G, Schulpis KH, Molou E, Georgiou V, Loukas YL, Dotsikas Y, et al. High incidence of Partial Biotinidase Deficiency cases in newborns of Greek origin. Gene. 2013.
5. Wolf B, Heard GS, Weissbecker KA, McVoy JRS, Grier RE, Leshner RT. Biotinidase deficiency: initial clinical features and rapid diagnosis. Annals of neurology. 1985;18(5):614-7.
6. Hymes J, Stanley CM, Wolf B. Mutations in BTD causing biotinidase deficiency. Human mutation. 2001;18(5):375-81.
7. Andersen JB, Blichfeldt S, Christensen MF, Haagerup A. Biotinidase deficiency: two cases of very early presentation. Developmental Medicine & Child Neurology. 1997;39(12):832-5.
8. Weber P, Scholl S, Baumgartner E. Outcome in patients with profound biotinidase deficiency: relevance of newborn screening. Developmental Medicine & Child Neurology. 2004;46(7):481-4.
9. Micó SI, Jiménez RD, Salcedo EM, Martínez HA, Mira AP, Fernández CC. Epilepsy in Biotinidase Deficiency After Biotin Treatment. JIMD Reports-Case and Research Reports, 2012/1: Springer; 2012. p. 75-8.
10. Brunetti-Pierri N, Parenti G, Andria G. Inborn Errors of Metabolism. Neonatology: Springer; 2012. p. 949-66.
11. Venkataraman V, Balaji P, Panigrahi D, Jamil R. Biotinidase deficiency in childhood. Neurology India. 2013;61(4).
12. Bunch M, Singh A. Peculiar neuroimaging and electrophysiological findings in a patient with biotinidase deficiency. Seizure. 2011;20(1):83-6.
13. Matern D. Acylcarnitines. Physician’s Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases: Springer; 2014. p. 775-84.